VEGFA and ovarian carcinoma: Triggered by the remarkable preclinical efficacy of bevacizumab (Avastin), a humanized VEGF blocking monoclonal antibody, in a range of solid tumor types, a series of clinical studies have been conducted to evaluate bevacizumab in patients with newly-diagnosed or recurrent ovarian cancer.